Xtant Medical Holdings Inc   (XTNT)

The Biotechnology & Pharmaceuticals company declared Sharp Top-line elevation , during the first quarter of 2023

company recorded first quarter of 2023 operating shortfall of $-1.576 million

Published 2023-05-17T04:53:46+00:00
Goran Soko / CSIMarket.com Contributer

Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_CommonsXTNT lost money at $-0.02 per share in the first quarter of 2023, although its revenue surged by 38.46 % to $17.94 million from the comparable quarter a year prior.

In the preceding quarter XTNT realized Revenue of $15.27 million and $-0.02 per share.

In the most recent fiscal period Xtant Medical Holdings Inc reported net shortfall of $-2.078 million, instead of deficit of $-2.213 million in the comparable quarter a year ago.

Xtant Medical Holdings Inc is expected to report next financial results on August 03, 2023.

Xtant Medical Holdings Inc's Operating Margin

Xtant Medical Holdings Inc's Dividend Pay out


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071